Trial Profile
An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial'
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms W-JHS NHL02-A study
- 18 Oct 2022 Planned End Date changed from 30 Jun 2022 to 30 Apr 2025.
- 11 Nov 2021 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
- 11 Nov 2021 Status changed from recruiting to active, no longer recruiting.